BioSpace News Archive

Tiziana Life Sciences Ltd. today announces that it has received a notification from the Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department informing the Company that it has regained compliance with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.

Health Canada has issued a Notice of Compliance (NOC) approving BEYFORTUS™ (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants during their first RSV season, and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

BrainStorm Cell Therapeutics Inc. today announced the appointment of Kirk Taylor, M.D., as Executive Vice President and Chief Medical Officer (EVP, CMO), effective May 1, 2023.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Phase 3 NEURO-TTRansform study for AstraZeneca and Ionis’ eplontersen in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group.

Ascensia Diabetes Care , a global diabetes care company, maker of the CONTOUR ® Blood Glucose Monitoring (BGM) system portfolio and exclusive distributor of Eversense ® Continuous Glucose Monitoring (CGM) Systems, marks the one-year anniversary of launching Eversense ® E3 in the U.S. with a commercial update and outlook on future innovation.

Visolis today announced a partnership with Ginkgo Bioworks which is building the leading platform for cell programming and biosecurity.

YourBio Health, Inc, the developers of the world’s first virtually painless push-button blood collection device, announced today that TAP® Micro Select received 510(k) Medical Device clearance from the U.S. Food and Drug Administration (FDA).

Viatris Inc. and Mapi Pharma today announced that recent data from ongoing studies of GA Depot 40 mg will be presented at the American Academy of Neurology (AAN) 75th Annual Meeting in Boston taking place April 22-27.

Despite the promise of new medications that promote cancer cell death in people with acute myeloid leukemia, leukemic cells often adopt features that let them evade the drugs’ effects within a year.

Nevro Corp. announced today that it is participating in the following investor conferences.